Industry landscapes
The companies, capital and talent shaping healthtech in Delhi. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
A few useful ratios bring the size of this ecosystem into perspective.
70 of 836 tracked companies have open roles.
83 of 836 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 160 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 70.6% of disclosed capital, while 90.1% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $17.72M | 46 | 10 |
| 2017 | $16.34M | 51 | 10 |
| 2018 | $91.08M | 41 | 14 |
| 2019 | $5.08M | 63 | 13 |
| 2020 | $42.18M | 61 | 11 |
| 2021 | $37.14M | 73 | 19 |
| 2022 | $94.99M | 65 | 19 |
| 2023 | $17.77M | 52 | 16 |
| 2024 | $27.83M | 38 | 16 |
| 2025 | $7.8M | 17 | 5 |
Share of all disclosed company funding.
190 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Turbostart and Idea Baaz and others.
Backed by Umesh Bhatt.
Backed by Steadview and Peak XV Partners and others.
Backed by Corisol Holding and IFC and others.
Backed by Steadview and Peak XV Partners and others.
Backed by KWE and HBM Healthcare Investments and others.
Backed by Blume Venture and HealthQuad and others.
Backed by Gates and Mauritius Africa Fund and others.
Backed by HBM Healthcare Investments and Mauritius Africa Fund and others.
Backed by Maverick Ventures and HBM Healthcare Investments and others.
Backed by Maverick Ventures and HBM Healthcare Investments and others.
Backed by HBM Healthcare Investments and Maverick Ventures and others.
Backed by Impanix Capital.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 241 reporting entities from 294 eligible matches.
Sum of reporting-entity revenue; not Delhi market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
139 of 241 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 241 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Dr.Morepen ↗L24231HP1984PLC006028 | ₹1,554.5 crore | ₹101.6 crore | +6.5% | — | ₹1,721.2 crore |
| Q-Line Biotech ↗U74120UP2010PLC042528 | ₹313.1 crore | ₹47.4 crore | +15.1% | — | ₹448.7 crore |
| Unicorn DenMart ↗U29297DL2008PLC173509 | ₹197.1 crore | ₹6.0 crore | +3.1% | — | ₹125.0 crore |
| Auxein Medical ↗U33110DL2012PTC241539 | ₹167.1 crore | ₹18.4 crore | +11.0% | — | ₹159.5 crore |
| Global Medikit ↗U33119DL2001PLC110470 | ₹140.8 crore | ₹8.9 crore | +6.3% | — | ₹89.3 crore |
| Mitra Industries ↗U74999DL1995PTC065200 | ₹134.6 crore | ₹21.6 crore | +16.0% | — | ₹129.9 crore |
| RD Plast ↗U25203DL2007PTC167905 | ₹60.0 crore | ₹2.7 crore | +4.5% | — | ₹27.7 crore |
| Wrig Nanosystems ↗U73100DL2009PTC195739 | ₹46.7 crore | ₹0.9 crore | +1.9% | — | ₹38.7 crore |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Delhi companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
12 of the 836 companies on this page carry a measured traffic record (1.4%); these are the largest of those, by monthly visits. The median among them is 107,160 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Tata 1mg1mg.com | 20,342,190 | 96 | 89% |
| Medical Dialoguesmedicaldialogues.in | 1,744,001 | 54 | 94.2% |
| Nutrabaynutrabay.com | 1,125,094 | 44 | 90.2% |
| AllDayChemistalldaychemist.com | 449,190 | 36 | 71.2% |
| DentalKartdentalkart.com | 261,128 | 40 | 86.7% |
| MedTalksmedtalks.in | 126,584 | 40 | 92% |
| Sheopal\'ssheopals.com | 87,736 | 31 | 95.3% |
| Dr.Morependrmorepen.com | 84,833 | 32 | 97% |
| NirogStreetnirogstreet.com | 72,592 | 33 | 93.1% |
| Egmedi.comegmedi.com | 49,740 | 31 | 91% |
Visits and authority are third-party web estimates, not company-reported figures.
96 of these companies (11.5%) publish at least one Android app — 146 apps in all, carrying 53.1M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| TATA 1mg Online Healthcare AppTata 1mg | 41.7M | 4.7 | Medical |
| Nutrabay: Supplements StoreNutrabay | 3M | 5 | Health & Fitness |
| BeatO: Diabetes Care AppBeatO | 2.6M | 4.3 | Health & Fitness |
| Dentalkart-Online Dental StoreDentalKart | 1.9M | 3.9 | Shopping |
| Healthmug - Healthcare AppHealthmug | 811.3K | 4.5 | Medical |
| vHealth (India)MediBuddy VHealth | 440.8K | — | Health & Fitness |
| Dr Morepen Sync Sugar & BP AppDr.Morepen | 244.5K | — | Health & Fitness |
| NirogStreetNirogStreet | 236.9K | — | Medical |
| Chiku – Journal & Mood TrackerChiku | 220.7K | 4.5 | Health & Fitness |
| Breathe Well-beingBreathe Well-Being | 198.4K | 4.7 | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare Booking Platforms | 58 | 49.7M | TATA 1mg Online Healthcare App 41.7M | |
| Disease Self Management | 24 | 3.6M | BeatO: Diabetes Care App 2.6M | |
| Fitness & Wellness Tech | 12 | 3.5M | Nutrabay: Supplements Store 3M | |
| Healthcare It | 57 | 2.4M | Dentalkart-Online Dental Store 1.9M | |
| Employee Health It | 5 | 190.5K | MindPeers: Online Therapy 172.9K | |
| Hrtech | 4 | 175.4K | TalktoAngel 2.4K | |
| Wearable Technology | 6 | 16.9K | Zivov 16.5K | |
| Traditional Medical Devices | 6 | 4.4K | Accuster LT 1.8K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 97 of 146 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
31 companies hiring · $399.84M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Elevate Now, a doctor‑led, root‑cause‑driven clinical weight loss platform, has raised ₹18 crore in seed funding, led by Physis Capital, with participation from Inflection Point Ventures and Titan Capital.
Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, announced that it has agreed to acquire a controlling stake in Paramount Surgimed, one of India’s largest manufacturers and exporters of surgical blades, scalpels and dermal biopsy products.
The healthtech startup is reportedly in advanced talks to raise around $200 Mn (INR 2,400 Cr) in yet another funding round.
Vasa Denticity Ltd. (NSE: DENTALKART), India’s fastest-growing dental products company and parent of the Dentalkart platform, has announced the strategic acquisition of 51% stake in IDS Denmed Pvt. Ltd.
Vaidam Health, a medical tourism company based in India, has acquired MediJourney, a digital-first platform for international patient facilitation that was incubated by Ferns N Petals (FNP) in 2024.
Celltech plc acquired Medeva last November, following its June 1999 $1 billion merger with Chiroscience Group plc.
dental essential focused marketplace DentalKart
D2C nutrition startup Nutrabay has secured $5 million in a Pre‑Series A funding round led by RPSG Capital Ventures. The round also saw participation from existing investors, including Kotak Alternate Asset Managers Limited.
TrioTree Technologies, a leading provider of healthcare IT solutions, is pleased to announce the appointment of Dr Rajesh Gupta as its new Chief Growth Officer.
Prega News, the pregnancy detection brand from Mankind Pharma, has appointed FCB Kinnect as its Full-Funnel Creative Agency on Record after a rigorous pitch process.
Top 7 categories among 32 recorded events in the 24-month window.
1 companies with recorded IPO activity
IPO1 reports
Products, platforms and features in the recorded window
Pet Care
1 companies with reported reductions
100 rolesbusiness downturn
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Entero Healthcare Solutions→Ace ↗ | Announced | 2026-01-31 | Not stated in snapshot |
| healthium medtech→paramount surgimed limited ↗ | Announced | 2025-12-15 | Not stated in snapshot |
| Vasa Denticity Ltd.→IDS Denmed ↗ | Announced | 2025-08-08 | Not stated in snapshot |
| Vaidam→MediJourney | Completed | 2025-06-23 | Not stated in snapshot |
| celltech→Medeva ↗ | Completed | 2025-02-14 | Not stated in snapshot |
| Matrix Pharmaceutical→Medeva ↗ | Completed | 2025-02-14 | $2.0M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
291 postings in the preceding 12 months. The full 339-posting snapshot covers 234 employers.
8 tracked postings mention remote work.
161 postings specify a level.
Top skills across 339 tracked postings in the available jobs snapshot.
Median across 56 postings with pay data, expressed in USD.
| Company | Open roles |
|---|---|
| Nutrabay ↗ | 6 |
| Elevate Now ↗ | 4 |
| Mamily ↗ | 4 |
| Ayuvya ↗ | 4 |
| Wrig Nanosystems ↗ | 3 |
| Momkidcare ↗ | 3 |
| Mindpeers ↗ | 2 |
| BeatO ↗ | 2 |
| Company | Employees |
|---|---|
| Mitra Industries ↗ | 375 |
| RD Plast ↗ | 375 |
| Q-Line Biotech ↗ | 270 |
| Accuster Technologies ↗ | 235 |
| TrioTree ↗ | 203 |
| BeatO ↗ | 188 |
| Auxein Medical ↗ | 177 |
| NirogStreet ↗ | 170 |
580 founders and chief executives across 413 companies.
Co-Founder-1mg · Ex-HealthKart, Zynga, Network Appliance, taproot foundation · IIT Delhi BTech 2001
Founder-LAT Aerospace · Founder-Temple, Founder-Eternal · Ex-Bain and Company · IIT Delhi 2005
Performics, ex-Smg Convonix, ex-Convonix, k.J somaiya college of Engineering, 2009
Ex-Founder & CEO The Marketech, Techlus
Co-Founder Impanix, EyeMantra Group of Hospital, ex-Mohan Eye Institute. Manipal Academy of Higher Education MBBS, Doane University MS 2020
Breathe Well-being · Ex-Co-Founder ClassHop, PA Consulting, Accenture · UCLA BS 2010
Ex-Dr Aggarwals Delhi Dental Clinic & Implant Centre. Maulana Azad Institute Of Dental Sciences BDS 2011
Ex-Mahajan Imaging, Mahajan Imaging, Religare Technologies. The Wharton School MBA
BREEDERS AND GROWERS. Maharshi Dayanand University Rohtak BTech 2013
Ex-Radicura Pharmaceuticals · SYMBIOSIS INTERNATIONAL UNIVERSITY 2011
Ex-DaoLens, Dukaan, Swiggy, POPxo, Uber. IIT Bombay BTech, MTech 2006, Indian School of Business MBA 2015
Co-Founder & CEO-Sychedelic · Ex-Co-Founder Neuphony, Infineon Technologies · Jaypee Institute Of Information Technology BTech 2015…
79 profiles with education records.
11 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
96,761 articles in the measured 12-month window.
Healthtech coverage tagged Delhi · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 24,120 |
| 2021Q3 | 15,641 |
| 2021Q4 | 14,907 |
| 2022Q1 | 17,176 |
| 2022Q2 | 20,375 |
| 2022Q3 | 22,352 |
| 2022Q4 | 21,607 |
| 2023Q1 | 27,631 |
| 2023Q2 | 22,697 |
| 2023Q3 | 22,051 |
| 2023Q4 | 20,659 |
| 2024Q1 | 20,309 |
| 2024Q2 | 20,892 |
| 2024Q3 | 21,538 |
| 2024Q4 | 24,020 |
| 2025Q1 | 28,527 |
| 2025Q2 | 20,173 |
| 2025Q3 | 25,895 |
| 2025Q4 | 25,457 |
| 2026Q1 | 23,414 |
Article volume measures coverage, not market sales.
83 recorded company events across 10 companies; percentages use that event total.
Healthtech coverage tagged Delhi · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
India comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 11,620 | 5,680 | 105% |
| bilateral trade | 4,610 | 2,437 | 89% |
| trade dispute mechanisms | 4,511 | 2,203 | 105% |
| trade barrier reduction | 4,496 | 2,440 | 84% |
| trade facilitation commitments | 4,327 | 2,201 | 97% |
| countries | 4,193 | 1,860 | 125% |
| free trade deals | 4,078 | 2,429 | 68% |
| multilateral diplomacy | 3,918 | 2,723 | 44% |
| diplomatic strategies | 3,816 | 2,350 | 62% |
| bilateral trade imbalance | 3,281 | 2,044 | 61% |
| odi cricket | 6,036 | 9,660 | -38% |
| limited overs cricket | 5,777 | 9,308 | -38% |
| odi tactics | 5,628 | 8,746 | -36% |
| odi series | 5,256 | 8,324 | -37% |
| odi tournaments | 5,032 | 8,067 | -38% |
India comparison coverage
territories, disputed islands, test cricket
44.3% critical · 27.2% positivepre-ipo valuation, ipo prospectus, ipo pricing
49.3% critical · 46.7% positivegdp growth rate, economic output growth, economic growth statistics
46.9% critical · 50.7% positiveHealthtech coverage tagged Delhi. Topic labels describe recorded classifications and can include broad context.
3,029 papers in the recorded india scope.
Tone counts: 2,771 positive · 35 neutral · 223 negative.
Landmark: Barriers and facilitators to utilizing digital health technologies by healthcare professionals
Landmark: Digital mental health apps and the therapeutic alliance: initial review
Landmark: Feature selection and classification systems for chronic disease prediction: A review
Common problems researchers identify · 0123.6% of this theme group
Researchers highlight rising drug resistance and challenges in diagnosing and treating infectious diseases.
Disease (84) · Human health (29) · Antibiotic resistance (37) · Medical device (35)
Leishmaniasis: A multifaceted approach to diagnosis, maladies, drug repurposing and way forward
Multitargeting: An Alternative Approach to Tackle Multidrug Resistancein Tuberculosis
| Year | Share index |
|---|---|
| 2022 | 1311.9 |
| 2023 | 1170.0 |
| 2024 | 1054.1 |
| 2025 | 1320.5 |
Common problems researchers identify · 0221.7% of this theme group
Papers point to barriers and uneven adoption of digital tools in public health and clinical care.
Digital health (175) · Health care (224) · Public health (93) · Health administration (49)
The intersection of technology and mental health: enhancing access and care
Digital Healthcare and Patient Transformation: Review Research and Future Agenda
| Year | Share index |
|---|---|
| 2022 | 449.4 |
| 2023 | 435.7 |
| 2024 | 441.9 |
| 2025 | 764.8 |
Common problems researchers identify · 0313.1% of this theme group
Studies discuss obstacles in applying genomic data to personalized cancer and ocular therapies.
Precision medicine (227) · Personalized medicine (137) · Cancer (39) · Genomics (22)
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Precision medicine in cancer treatment: Revolutionizing care through proteomics, genomics, and personalized therapies
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Common problems researchers identify · 0411.7% of this theme group
Authors note technical, ethical, and workflow issues when embedding AI and big‑data analytics in medicine.
Health care (131) · Wearable computer (36) · Big data (33) · Applications of artificial intelligence (24)
Artificial Intelligence in Healthcare: Transforming the Future of Medicine
Artificial intelligence and machine learning in healthcare: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 43.0 |
| 2023 | 45.3 |
| 2024 | 47.8 |
| 2025 | 86.2 |
Common problems researchers identify · 0510.9% of this theme group
Research identifies limitations in current screening, synthesis, and development pipelines for new therapeutics.
Drug discovery (213) · Drug (105) · Natural product (37) · Drug development (57)
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Drug Discovery and Development Processes
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 159.2 |
| 2024 | 166.2 |
| 2025 | 206.1 |
Common problems researchers identify · 0610.0% of this theme group
Works examine infrastructure, regulatory, and patient‑acceptance barriers to remote clinical services.
Telemedicine (193) · Health care (120) · Telehealth (46) · Medical emergency (22)
Telemedicine for healthcare: Capabilities, features, barriers, and applications
Exploring the potential of telemedicine for improved primary healthcare in India: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 215.3 |
| 2023 | 197.2 |
| 2024 | 209.5 |
| 2025 | 199.0 |
Common problems researchers identify · 078.9% of this theme group
Literature reports on the rapid scaling issues of telemedicine during COVID‑19 outbreaks.
Pandemic (159) · Coronavirus disease 2019 (124) · Telemedicine (110) · 2019-20 coronavirus outbreak (21)
Telehealth and the COVID-19 Pandemic: International Perspectives and a Health Systems Framework for Telehealth Implementation to Support Cri
Comprehending Telemedicine: An Online Survey amidst COVID-19 Pandemic
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Cautions · 0122.9% of this theme group
Cautionary papers warn about uncertainties in genotype‑guided drug dosing for cancer patients.
Pharmacogenomics (12) · Drug (21) · Precision medicine (16) · Cancer (10)
Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics
INVESTIGATIONAL THERAPIES AND TARGETED APPROACHES IN METAPLASTIC BREAST CANCER: A SYSTEMATIC REVIEW OF EMERGING PHARMACOLOGICAL STRATEGIES
| Year | Share index |
|---|---|
| 2022 | 141.0 |
| 2023 | 147.0 |
| 2024 | 157.4 |
| 2025 | 213.9 |
Cautions · 0220.0% of this theme group
Authors caution that AI models may lack robustness and transparency for clinical decision‑making.
Applications of artificial intelligence (20) · Big data (15) · Precision medicine (26) · Health care (42)
Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine
Artificial intelligence (AI): using ai to assist in patient assessment, diagnostics, and clinical decision-making
| Year | Share index |
|---|---|
| 2022 | 27.5 |
| 2023 | 30.3 |
| 2024 | 35.4 |
| 2025 | 89.2 |
Cautions · 0314.5% of this theme group
Studies stress limited evidence on outcomes for geriatric and postoperative patients using remote care.
Telemedicine (54) · Health care (38) · Telerehabilitation (8) · Medical emergency (8)
Telemedicine in Geriatric Psychiatry: Relevance in India
Telemedicine Versus In-Person Visits in Postoperative Care in Orthopedic Patients: Follow-Up Study From North India
| Year | Share index |
|---|---|
| 2022 | 213.6 |
| 2023 | 195.8 |
| 2024 | 207.4 |
| 2025 | 194.7 |
Cautions · 0412.7% of this theme group
Research questions whether technology truly improves care quality or adds complexity for users.
Health care (33) · Digital health (18) · Public health (10) · Health informatics (10)
Utilizing Digital Health Technologies To Improve Patient Experience And Care Quality In Global Healthcare: A Systematic Review
An impact of digital technologies on healthcare and patient outcomes: A review
| Year | Share index |
|---|---|
| 2022 | 453.1 |
| 2023 | 438.9 |
| 2024 | 445.9 |
| 2025 | 773.9 |
Cautions · 0510.5% of this theme group
Papers highlight over‑reliance on algorithms without sufficient experimental validation.
Drug discovery (35) · Drug (22) · Drug development (11) · Repurposing (8)
Exploring AI-driven approaches to drug discovery and development
The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Cautions · 069.9% of this theme group
Analyses critique inconsistent evidence for digital interventions on psychological well‑being.
Mental health (22) · Psychological intervention (20) · Digital health (20) · Intervention (5)
Digital wellness or digital dependency? a critical examination of mental health apps and their implications
The Role of Technology in Mental Health: Evaluating Digital Interventions for Psychological Well-being
| Year | Share index |
|---|---|
| 2022 | 784.7 |
| 2023 | 800.0 |
| 2024 | 802.5 |
| 2025 | 1143.3 |
Cautions · 079.5% of this theme group
Authors note mixed patient satisfaction results and potential fatigue with virtual visits.
Pandemic (32) · Coronavirus disease 2019 (22) · Telemedicine (25) · Telehealth (13)
A Review of Patient Satisfaction and Experience with Telemedicine: A Virtual Solution During and Beyond COVID-19 Pandemic
International survey of audiologists during the COVID-19 pandemic: use of and attitudes to telehealth
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Opportunities · 0117.9% of this theme group
Opportunities focus on leveraging plant and fungal compounds for novel therapeutic agents.
Drug discovery (338) · Drug (231) · Combinatorial chemistry (69) · Health benefits (48)
Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Disco
Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems
| Year | Share index |
|---|---|
| 2022 | 164.8 |
| 2023 | 169.5 |
| 2024 | 181.6 |
| 2025 | 220.1 |
Opportunities · 0217.6% of this theme group
Papers explore deep‑learning models to enhance disease detection and personalized treatment planning.
Health care (352) · Convolutional neural network (91) · Applications of artificial intelligence (54) · Chatbot (50)
AI in Healthcare: Opportunities and Challenges for Personalized Medicine and Disease Diagnosis
AI-Driven Healthcare Solutions: Utilizing Deep Learning for Predictive Analytics and Personalized Medicine
| Year | Share index |
|---|---|
| 2022 | 36.8 |
| 2023 | 39.0 |
| 2024 | 29.7 |
| 2025 | 47.6 |
Opportunities · 0315.7% of this theme group
Research highlights new biomarkers and computational methods to tailor cancer therapies.
Precision medicine (419) · Personalized medicine (304) · Cancer (216) · Biomarker (72)
Addressing Challenges and Opportunities in Precision Medicine Using Deep Learning and Personalized Cancer Treatment
Precision and personalized medicine: new way for cancer management
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Opportunities · 0413.8% of this theme group
Studies showcase remote care models improving access and outcomes for long‑term conditions.
Telemedicine (357) · Health care (305) · Telehealth (103) · Digital health (135)
Optimizing healthcare outcomes and broadening nursing capabilities in digital era: telemedicine transformative impact
Advancing Public Health: A Comprehensive Analysis of Telemedicine in Chronic Disease Management, Access Improvement, and Health Promotion Pr
| Year | Share index |
|---|---|
| 2022 | 65.1 |
| 2023 | 64.6 |
| 2024 | 63.7 |
| 2025 | 106.3 |
Opportunities · 0512.9% of this theme group
Works emphasize virtual modeling to accelerate antiviral and therapeutic candidate identification.
Virtual screening (376) · Docking (374) · In silico (288) · Computational biology (210)
<i>In Silico</i>molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2
Insights into novel inhibitors intending HCMV protease a computational molecular modelling investigation for antiviral drug repurposing
| Year | Share index |
|---|---|
| 2022 | 28.9 |
| 2023 | 30.4 |
| 2024 | 28.8 |
| 2025 | 32.8 |
Opportunities · 0611.5% of this theme group
Papers present strategies to find new uses for existing drugs using computational chemistry.
Drug discovery (513) · Drug (300) · Drug development (107) · Drug repositioning (82)
Drug repurposing: An emerging approach to drug discovery
LEVERAGING ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY: ADVANCES IN DRUG SYNTHESIS, DEVELOPMENT AND DESIGN
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Opportunities · 0710.6% of this theme group
Research outlines wearable and sensor networks for continuous health tracking in underserved areas.
Remote patient monitoring (196) · Internet of Things (170) · Wearable computer (170) · Health care (244)
IoT-Driven Smart Healthcare Systems for Remote Patient Monitoring and Management
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.1 |
| 2023 | 42.4 |
| 2024 | 45.7 |
| 2025 | 72.4 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 32.3% | 36.8% |
| Breakthrough | 27.0% | 26.8% |
| Problem-identifying | 21.8% | 9.4% |
| Descriptive | 10.8% | 17.8% |
| Cautionary | 5.2% | 4.3% |
| Comparative | 2.4% | 4.0% |
| Critical | 0.6% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSocial Connectedness, Excessive Screen Time During COVID-19 and Mental Health: A Review of Current Evidence | 370 | 3.08% | 131 (35.4%) | 2.66% |
| Safety & misusePolitical dimensions of misinformation, trust, and vaccine confidence in a digital age | 11 | 0.09% | 7 (63.6%) | 0.17% |
| Hardware, e-waste & supply chainE-wastes Management in AI Context: The Opportunities and Challenges in Educational and Healthcare Waste – <i>A Scientifi | 5 | 0.04% | 1 (20.0%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 4 | 0.03% | 3 (75.0%) | 0.01% |
| Carbon & emissions of computeFrom Opaqueness to Transparency: Sustainable AI in Diabetes Prediction | 1 | 0.01% | 0 (0.0%) | 0.0% |
| Labour & data workGIG worker protections: designing a new labour category for the digital economy | 1 | 0.01% | 1 (100.0%) | 0.01% |
| Bias & fairnessA Comprehensive Review of Bias and Fairness in Artificial Intelligence for Oral Cancer Detection | 1 | 0.01% | 1 (100.0%) | 0.06% |
| Concentration of compute powerRole of Artificial Intelligence, Big Tech and Machine Learning in Accelerating Biologics Development and Clinical Trials | 1 | 0.01% | 0 (0.0%) | 0.01% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: India. This may be broader than the company geography.
Published patent filings in the recorded source window.
Compare demand signals in Delhi’s newsflow with the healthtech categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Ageing & elder care ↗Disease Burden | 57.1 | 0.0 | +57.1 | +65.0% | |
| Mental health ↗Disease Burden | 72.9 | 50.0 | +22.9 | +25.4% | |
| Cancer burden ↗Disease Burden | 68.6 | 100.0 | -31.4 | +57.4% | |
| Air pollution ↗Environmental Driver | 70.0 | — | No matching category | — | +14.2% |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 60.7 | — | No matching category | — | — |
| Infectious outbreaks ↗Disease Burden | 21.4 | — | No matching category | — | -27.2% |
| Maternal & child health ↗Disease Burden | 24.3 | — | No matching category | — | -16.6% |
| Layoffs & income shocks ↗Spending Pressure | 25.0 | — | No matching category | — | — |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. Delhi is highlighted.
Each city’s reading is a share of its own coverage. Rows cover all of India for this page's signal families; Delhi is marked.
Air pollution · Mental health · Ageing & elder care
Air pollution · Mental health · Diabetes, hypertension & cardiac burden
Air pollution · Mental health · Maternal & child health
Mental health · Maternal & child health · Air pollution
Air pollution · Mental health · Layoffs & income shocks
Diabetes, hypertension & cardiac burden · Mental health · Air pollution
Mental health · Maternal & child health · Infectious outbreaks
Mental health · Ageing & elder care · Infectious outbreaks
Mental health · Infectious outbreaks · Maternal & child health
Mental health · Maternal & child health · Infectious outbreaks
Mental health · Maternal & child health · Infectious outbreaks
Mental health · Air pollution · Infectious outbreaks
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 15 | 4.4 |
| 2024Q4 | 6 | 1.67 |
| 2025Q1 | 22 | 5.76 |
| 2025Q2 | 8 | 3.48 |
| 2025Q3 | 29 | 8.51 |
| 2025Q4 | 18 | 5.73 |
| 2026Q1 | 16 | 5.63 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 81 | 23.76 |
| 2024Q4 | 95 | 26.36 |
| 2025Q1 | 96 | 25.14 |
| 2025Q2 | 44 | 19.16 |
| 2025Q3 | 107 | 31.39 |
| 2025Q4 | 138 | 43.94 |
| 2026Q1 | 84 | 29.54 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 16 | 4.69 |
| 2024Q4 | 23 | 6.38 |
| 2025Q1 | 19 | 4.98 |
| 2025Q2 | 17 | 7.4 |
| 2025Q3 | 32 | 9.39 |
| 2025Q4 | 19 | 6.05 |
| 2026Q1 | 30 | 10.55 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 309 | 90.64 |
| 2024Q4 | 2246 | 623.28 |
| 2025Q1 | 526 | 137.76 |
| 2025Q2 | 277 | 120.62 |
| 2025Q3 | 328 | 96.21 |
| 2025Q4 | 2210 | 703.69 |
| 2026Q1 | 483 | 169.87 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 9 | 2.64 |
| 2024Q4 | 7 | 1.94 |
| 2025Q1 | 18 | 4.71 |
| 2025Q2 | 35 | 15.24 |
| 2025Q3 | 45 | 13.2 |
| 2025Q4 | 28 | 8.92 |
| 2026Q1 | 13 | 4.57 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 34 | 9.97 |
| 2024Q4 | 19 | 5.27 |
| 2025Q1 | 70 | 18.33 |
| 2025Q2 | 26 | 11.32 |
| 2025Q3 | 37 | 10.85 |
| 2025Q4 | 21 | 6.69 |
| 2026Q1 | 15 | 5.28 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 40 | 11.73 |
| 2024Q4 | 22 | 6.11 |
| 2025Q1 | 22 | 5.76 |
| 2025Q2 | 16 | 6.97 |
| 2025Q3 | 29 | 8.51 |
| 2025Q4 | 19 | 6.05 |
| 2026Q1 | 26 | 9.14 |
Layoff cycles can pull discretionary spend back toward value offerings.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 12 | 3.52 |
| 2024Q4 | 9 | 2.5 |
| 2025Q1 | 8 | 2.1 |
| 2025Q2 | 22 | 9.58 |
| 2025Q3 | 15 | 4.4 |
| 2025Q4 | 17 | 5.41 |
| 2026Q1 | 19 | 6.68 |
Delhi healthtech coverage
BMC Microbiology
494 citations in the snapshot
Journal of Fungi
101 citations in the snapshot
PubMed
96 citations in the snapshot
Antimicrobial Agents and Chemotherapy
86 citations in the snapshot
Delhi coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| disease outbreak deaths | 18 | 8 | 155.5% |
| urban sustainability | 23 | 11 | 137.4% |
| healthy diet cancer | 15 | 10 | 70.3% |
| particulate filters | 61 | 45 | 53.9% |
| vehicular emissions | 152 | 113 | 52.7% |
| clean air advocacy | 194 | 193 | 14.1% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 5 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗